An overview of the clinical pharmacology of enalapril.

A new class of angiotensin-converting enzyme inhibitors

1980 • 704 citations

Antihypertensive therapy with MK 421: angiotensin II--renin relationships to evaluate efficacy of converting enzyme blockade.

1982 • 243 citations

Enalapril improves systemic and renal hemodynamics and allows regression of left ventricular mass in essential hypertension

1984 • 239 citations

Contribution of prostaglandins to the antihypertensive action of captopril in essential hypertension.

1981 • 219 citations

Enalapril maleate and a lysine analogue (MK‐521): disposition in man.

1982 • 213 citations

Regression of left ventricular hypertrophy from systemic hypertension by enalapril

1984 • 211 citations

ANTIHYPERTENSIVE EFFECT OF THE NEW ORAL ANGIOTENSIN CONVERTING ENZYME INHIBITOR "MK-421".

1981 • 189 citations

Antihypertensive Therapy with MK 4211

1982 • 188 citations

Disposition of captopril in normal subjects

1980 • 161 citations

The Relationship of Blood Pressure to Diet and Lifestyle in Two Religious Populations

1983 • 153 citations

Three new long-acting converting-enzyme inhibitors: Relationship between plasma converting-enzyme activity and response to angiotensin I

1981 • 146 citations

Effect of N-[(S)-1-carboxy-3-phenylpropyl]-L-Ala-L-Pro and its ethyl ester (MK-421) on angiotensin converting enzyme in vitro and angiotensin I pressor responses in vivo.

1981 • 146 citations

The physiological disposition and metabolism of enalapril maleate in laboratory animals.

1982 • 134 citations

Hemodynamic and clinical response to enalapril, a long-acting converting-enzyme inhibitor, in patients with congestive heart failure.

1984 • 126 citations

Effect of a new angiotensin converting enzyme inhibitor MK 421 and its lysine analogue on the components of the renin system in healthy subjects.

1981 • 124 citations

Pharmacodynamics of converting enzyme inhibition: the cardiovascular, endocrine and autonomic effects of MK421 (enalapril) and MK521.

1982 • 119 citations

Antihypertensive activity of N-[(S)-1-(ethoxycarbonyl)-3-phenylpropyl]-L-Ala-L-Pro (MK-421), an orally active converting enzyme inhibitor.

1981 • 119 citations

Effect of a new angiotensin converting enzyme inhibitor MK 421 and its lysine analogue on the components of the renin system in healthy subjects

2004 • 114 citations

Enalapril maleate and a lysine analogue (MK‐521) in normal volunteers; relationship between plasma drug levels and the renin angiotensin system.

1982 • 109 citations

Enalapril: A new angiotensin-converting enzyme inhibitor in chronic heart failure: Acute and chronic hemodynamic evaluations

1983 • 106 citations

Enalapril Worldwide Experience

1984 • 105 citations

Effects of enalapril, a new converting enzyme inhibitor, in hypertension

1982 • 83 citations

Enalapril Maleate (MK-421), a Potent, Nonsulfhydryl Angiotensin-Converting Enzyme Inhibitor: Absorption, Disposition, and Metabolism in Man

1983 • 82 citations

Non-sulfhydryl-containing angiotensin-converting enzyme inhibitor (MK421): evidence for role of renin system in normotensive subjects.

1981 • 70 citations

Endogenous Angiotensin II as a Determinant of Sodium-Modulated Changes in Tissue Responsiveness to Angiotensin II in Normal Man*

1983 • 68 citations

Acute and Chronic Effects of the Converting Enzyme Inhibitors Enalapril and Lisinopril on Reflex Control of Heart Rate in Normotensive Man

1985 • 67 citations

Enalapril (MK421) and its lysine analogue (MK521): a comparison of acute and chronic effects on blood pressure, renin‐angiotensin system and sodium excretion in normal man.

1984 • 65 citations

Comparison of oral MK 421 and propranolol in mild to moderate essential hypertension and their effects on arterial and venous vessels of the forearm

1984 • 65 citations

Evaluation of a long-acting converting enzyme inhibitor (Enalapril) for the treatment of chronic congestive heart failure

1983 • 65 citations

Role of Angiotensin Converting Enzyme Inhibitors in Essential and Renal Hypertension

1984 • 64 citations

Role of Prostaglandin in the Antihypertensive Mechanism of Captopril in Low Renin Hypertension

1980 • 61 citations

Increased renal plasma flow in long-term enalapril treatment of hypertension

1983 • 57 citations

Use of First-Dose Response or Plasma Renin Activity to Predict the Long-Term Effect of Captopril

1980 • 54 citations

Reflex-hemodynamic adjustments and baroreflex sensitivity during converting enzyme inhibition with MK-421 in normal humans.

1983 • 53 citations

Haemodynamic, hormonal, and electrolyte effects of enalapril in heart failure.

1983 • 51 citations

Clinical pharmacology of enalapril.

1984 • 51 citations

Time Course and Effect of Sodium Intake on Vascular and Hormonal Responses to Enalapril (MK 421) in Normal Subjects

1983 • 49 citations

Enalapril in the treatment of hypertension with renal artery stenosis.

1983 • 48 citations

Cardiac and haemodynamic effects of enalapril.

1983 • 48 citations

Relationship between angiotensin I blockade and antihypertensive properties of single doses of MK-421 and captopril in spontaneous and renal hypertensive rats

1981 • 45 citations

Converting-enzyme inhibitor enalapril (MK421) in treatment of hypertension with renal artery stenosis.

1982 • 39 citations

Enalapril (MK421) in the treatment of hypertension with renal artery stenosis.

1983 • 37 citations

Relationship of antihypertensive effect of enalapril to serum MK-422 levels and angiotensin converting enzyme inhibition.

1983 • 37 citations

A Comparison of Minoxidil and Hydralazine in Non-azotemic Hypertensives

1983 • 36 citations

Hypertension and the angiotensin system. Therapeutic approaches

1984 • 35 citations

Duration of Action and Short-Term Hormonal Responses to Enalapril (MK 421) in Normal Subjects

1984 • 35 citations

Antihypertensive and metabolic effects of a new converting enzyme inhibitor, enalapril

1983 • 34 citations

Comparative Antihypertensive Effects of Enalapril Maleate and Hydrochlorothiazide, Alone and in Combination

1983 • 33 citations

Hemodynamic and antihypertensive effects of the new oral angiotensin-converting-enzyme inhibitor MK-421 (enalapril).

1984 • 32 citations

Immunoreactive bradykinin and [des-Arg9]-bradykinin in low-renin essential hypertension--before and after treatment with enalapril (MK 421).

1983 • 31 citations

Humoral and Renal Effects of MK-421 (Enalapril) in Hypertensive Subjects

1983 • 27 citations

Plasma enalapril levels and hormonal effects after short‐ and long‐term administration in essential hypertension.

1984 • 26 citations

Enalapril in low-renin essential hypertension

1983 • 25 citations

Reversal of diuretic-induced secondary hyperaldosteronism and hypokalemia by enalapril (MK-421): A new angiotensin-converting enzyme inhibitor

1983 • 24 citations

The renin--angiotensin system in refractory heart failure: clinical, hemodynamic and hormonal effects of captopril and enalapril

1983 • 24 citations

The Therapeutic use of a new Potassium-Sparing Diuretic, Amiloride, and a Converting Enzyme Inhibitor, Mk-421, in Preventing Hypokalemia Associated with Primary and Secondary Hyperaldosteronism

1983 • 23 citations

Mechanism for Hypotensive Action of Angiotensin Converting Enzyme Inhibitors

1984 • 23 citations

Enalapril and autonomic reflexes and exercise performance.

1983 • 22 citations

BIOAVAILABILITY OF ENALAPRIL MALEATE

1984 • 20 citations

Enalapril (MK-421), A New Angiotensin-Converting Enzyme Inhibitor

1983 • 20 citations

Correlation between angiotensin converting enzyme inhibition and the acute hypotensive response to MK 421 in essential hypertension.

1982 • 19 citations

Converting enzyme inhibition to identify and treat renin-mediated or sodium-volume related forms of increased peripheral resistance in hypertension and in congestive heart failure.

1983 • 17 citations

Cardiac and hormonal effects of enalapril in hypertension

1983 • 17 citations

Temporal enhancement of renin-aldosterone blockade by enalapril, an angiotensin-converting enzyme inhibitor

1982 • 16 citations

Effects of enalapril on blood pressure and renal haemodynamics in essential hypertension.

1983 • 11 citations

Effects of a new angiotensin-converting enzyme inhibitor, MK 421, in normal men and patients.

1982 • 7 citations

Altered Fractional Tetrahydroaldosterone Excretion during Pharmacological Blockade and Activation of the Renin-Aldosterone System*

1982 • 7 citations